The difference between now, today, and last July is the broader awareness of just what CLSN has as far as potential and the shortening time span that it might take to achieve that potential.
People are upgrading their target analysis. People are seeing CLSN as having a relatively cheap market cap in relation to some peers in PIII biotech who have small pipelines, eg. KERX OREX.
There are only 28.8 million shares in the float and institutions are going to want some and there won't be enough to go around.
When you see a gap, that sounds an alarm, but you have to sit back and analyze what it means and where it goes from here, IMO.
Market Data 
Markets 
AI
